BRPI0407795A - polimorfos de inibidores de proteìna cinase de 2-indolinona substituìda com pirrol - Google Patents

polimorfos de inibidores de proteìna cinase de 2-indolinona substituìda com pirrol

Info

Publication number
BRPI0407795A
BRPI0407795A BRPI0407795-4A BRPI0407795A BRPI0407795A BR PI0407795 A BRPI0407795 A BR PI0407795A BR PI0407795 A BRPI0407795 A BR PI0407795A BR PI0407795 A BRPI0407795 A BR PI0407795A
Authority
BR
Brazil
Prior art keywords
pyrrol
substituted
protein kinase
kinase inhibitors
polymers
Prior art date
Application number
BRPI0407795-4A
Other languages
English (en)
Inventor
Changquan Sun
Todd P Foster
Fusen Han
Michael Hawley
Tom Thamann
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of BRPI0407795A publication Critical patent/BRPI0407795A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"POLIMORFOS DE INIBIDORES DE PROTEìNA CINASE DE 2-INDOLINONA SUBSTITUìDA COM PIRROL". A presente invenção refere-se polimorfos do composto de 2-indolinona substituída com 3-pirrol de (2-pirrolidin-1-il-etil)-amida de ácido 5-(5-flúor-2-oxo-1,2-dihidro-indol-3-ilidenometil)-2,4-dimetil-1H-pirrol-3- carboxílico.
BRPI0407795-4A 2003-02-24 2004-02-23 polimorfos de inibidores de proteìna cinase de 2-indolinona substituìda com pirrol BRPI0407795A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44886303P 2003-02-24 2003-02-24
US10/776,337 US7452913B2 (en) 2003-02-24 2004-02-12 Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
PCT/US2004/005281 WO2004076410A2 (en) 2003-02-24 2004-02-23 Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0407795A true BRPI0407795A (pt) 2006-02-14

Family

ID=32930498

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407795-4A BRPI0407795A (pt) 2003-02-24 2004-02-23 polimorfos de inibidores de proteìna cinase de 2-indolinona substituìda com pirrol

Country Status (15)

Country Link
US (2) US7452913B2 (pt)
EP (2) EP2258699A1 (pt)
JP (1) JP2006518755A (pt)
KR (1) KR20050107588A (pt)
AU (1) AU2004215407C1 (pt)
BR (1) BRPI0407795A (pt)
CA (1) CA2516900A1 (pt)
HK (1) HK1086486A1 (pt)
MX (1) MXPA05008959A (pt)
NO (1) NO20054071L (pt)
NZ (1) NZ541720A (pt)
PL (1) PL378570A1 (pt)
RU (1) RU2335502C2 (pt)
WO (1) WO2004076410A2 (pt)
ZA (1) ZA200506370B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452913B2 (en) * 2003-02-24 2008-11-18 Pharmacia & Upjohn Company Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
AU2006293644B2 (en) * 2005-09-19 2012-05-31 Zoetis Services Llc Solid salt forms of a pyrrole substituted 2-indolinone
TWI387019B (zh) * 2007-08-02 2013-02-21 Advanced Semiconductor Eng 在基材上形成穿導孔之方法
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
WO2011110199A1 (en) 2010-03-10 2011-09-15 Synthon B.V. A process for amidation of pyrrole carboxylate compounds
AU2011329656B2 (en) 2010-11-19 2017-01-05 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US9474756B2 (en) 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
PT1255536E (pt) * 1999-12-22 2006-09-29 Sugen Inc Derivados de indolinona para a modulacao da tirosina proteina cinase de tipo c-kit
US6339100B1 (en) * 1999-12-29 2002-01-15 The Trustees Of Columbia University In The City Of New York Methods for inhibiting mastocytosis
SK287142B6 (sk) * 2000-02-15 2010-01-07 Sugen, Inc. Inhibítory proteínkináz na báze pyrolom substituovaného 2-indolinónu, farmaceutický prípravok s ich obsahom a ich použitie
TWI270545B (en) * 2000-05-24 2007-01-11 Sugen Inc Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6797725B2 (en) * 2001-04-09 2004-09-28 Sugen, Inc. Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
MXPA04006992A (es) * 2002-02-15 2004-11-10 Upjohn Co Procedimiento para preparar derivados de indolinona.
US7452913B2 (en) * 2003-02-24 2008-11-18 Pharmacia & Upjohn Company Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors

Also Published As

Publication number Publication date
AU2004215407A1 (en) 2004-09-10
US20040259929A1 (en) 2004-12-23
HK1086486A1 (en) 2006-09-22
NZ541720A (en) 2009-02-28
WO2004076410A8 (en) 2005-10-20
WO2004076410A2 (en) 2004-09-10
JP2006518755A (ja) 2006-08-17
EP1599200A4 (en) 2007-02-07
NO20054071L (no) 2005-10-13
US20090048327A1 (en) 2009-02-19
WO2004076410A3 (en) 2005-03-03
US7452913B2 (en) 2008-11-18
EP2258699A1 (en) 2010-12-08
EP1599200A2 (en) 2005-11-30
PL378570A1 (pl) 2006-05-02
NO20054071D0 (no) 2005-09-01
RU2335502C2 (ru) 2008-10-10
ZA200506370B (en) 2006-12-27
KR20050107588A (ko) 2005-11-14
CA2516900A1 (en) 2004-09-10
RU2005129743A (ru) 2006-02-10
AU2004215407C1 (en) 2009-07-09
MXPA05008959A (es) 2005-11-04

Similar Documents

Publication Publication Date Title
BRPI0519597A2 (pt) derivados de (3r, 6r)-3-(2, 3-diidro-1h-inden-2-il)-2, 5-piperazinadiona 1, 6-substituÍda como antagonistas de receptores de oxitocina para o tratamento de parto prematuro, dismenorrÉia e endometriose
RS53599B1 (en) PIRIDON DERIVATIVES FOR STRESS MODULATION OF ACTIVATED PROTEIN KINASE SYSTEMS
EA200800701A1 (ru) 4-замещенные пирролидин-2-оны и их применение
EA200701121A1 (ru) Потенциаторы рецепторов глутамата
GT200500226A (es) Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa
WO2004069793A3 (en) Novel 2-substituted cyclic amines as calcium sensing receptor modulators
TW200626559A (en) Anilino-pyrimidine analogs
ATE349434T1 (de) Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten
MX2007003377A (es) Agonistas del receptor de trombopoyetina.
EA200301073A1 (ru) N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора
EA200802210A1 (ru) Замещенные пролинамиды, их получение и их применение в качестве лекарственных средств
ATE516291T1 (de) Thenopyrimidin-verbindungen mit fungizider aktivität
BRPI0411414A (pt) derivados de quinolil amida como antagonistas de cdr-5
BRPI0509731A (pt) pirazol[4,3-d]pirimidinas
EA200970372A1 (ru) Ингибитор развития болезни альцгеймера, содержащий гетероциклическое соединение
ATE469896T1 (de) Aminosäuresalze von rosiglitazon
BRPI0407795A (pt) polimorfos de inibidores de proteìna cinase de 2-indolinona substituìda com pirrol
ATE411287T1 (de) Neue metallproteinaseinhibitoren
ATE496056T1 (de) Pyrimidinverbindungen mit phosphonatgruppen als antivirale nucleotidanaloga
BRPI0416678A (pt) pirazolpirimidinas
HRP20090011T3 (en) 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl-piperidines used as cgrp antagonists
CY1109326T1 (el) Στερεες μορφες αλατος μια πυρρολο υποκατεστημενης 2-ινδολινονης
UY28204A1 (es) Polimorfos de inhibidores de proteína quinasa de 2-indolinona sustituida con pirrol
MA30656B1 (fr) Composes organiques
CR7991A (es) Proceso para la sintesis de 3- ciano- 6- alcoxy-7-nitro-4-quinolonas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/404; C07D 403/14; A61P 35/00

Ipc: A61K 31/404 (2011.01), C07D 403/14 (2011.01), A61P

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2307 DE 24/03/2015.